Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



## **CSPC PHARMACEUTICAL GROUP LIMITED**

## 石藥集團有限公司

(Incorporated in Hong Kong with limited liability)
(Stock code: 1093)

## DESPATCH OF CIRCULAR IN RELATION TO (1) GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME AND

## (2) APPLICATION FOR WHITEWASH WAIVER

References are made to the announcement of CSPC Pharmaceutical Group Limited (the "Company") dated 4 September 2023 and the circular of the Company dated 9 October 2023 (the "Circular") in relation to, among others, Mr. Cai's Share Options, the Underlying Transaction and the Whitewash Waiver. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Board wishes to announce that the Circular containing, among other things, (i) further details of Mr. Cai's Share Options; (ii) further details of the Underlying Transaction and the Whitewash Waiver; (iii) the letter from the Independent Board Committee; (iv) the recommendations from the Independent Financial Adviser on the Underlying Transaction and the Whitewash Waiver; (v) a notice convening the EGM; and (vi) additional information as required under the Listing Rules and the Takeovers Code, has been despatched to the Shareholders on 9 October 2023.

The EGM will be held at 10:00 a.m. on Friday, 3 November 2023 at Suite 3206, 32/F, Central Plaza, 18 Harbour Road, Wan Chai, Hong Kong, details of which are set out in the notice of the EGM despatched to the Shareholders on 9 October 2023.

The Shareholders are encouraged to read the Circular carefully, and in particular the letter from the Independent Board Committee to the Independent Shareholders and the letter from the Independent Financial Adviser to the Independent Board Committee, before deciding as to how to vote on the resolutions for approving, among other things, Mr. Cai's Share Options, the Underlying Transaction and the Whitewash Waiver.

WARNING: Shareholders and potential investors of the Company should note that the grant and Exercise of the Share Options and the Whitewash Waiver are subject to the satisfaction of the conditions set out in the section headed "Grant Conditions of the Share Options" in the letter from the Board in the Circular and therefore may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company, and are recommended to consult their professional advisers if they are in any doubt about their position and actions that they should take.

By order of the Board

CSPC Pharmaceutical Group Limited

CAI Dongchen

Chairman

Hong Kong, 9 October 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statement in this announcement misleading.